Establishes New Jersey Pharmacogenomics Commission.

SJR 31 establishes the New Jersey Pharmacogenomics Commission to study how a person's genetic makeup affects medication effectiveness and safety (pharmacogenomics). The 13-member commission, appointed by the Governor and legislative leaders, will examine costs, benefits for patients and providers, applications like opioid crisis response, and potential reductions in adverse drug events. It must hold public hearings in northern and southern New Jersey within six months of forming and submit a final report to the Governor and Legislature within six months of its organization. The commission expires after submitting this report, which will inform potential future policy decisions. This is a study commission only - no new laws or funding are created by the bill.